Zomedica Pharmaceuticals Overview

  • Status
  • Public

  • Employees
  • 141

Employees

  • Stock Symbol
  • ZOMDF

Stock Symbol

  • Investments
  • 7

  • Share Price
  • $0.08
  • (As of Friday Closing)

Zomedica Pharmaceuticals General Information

Description

Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its segments consist of Diagnostics, Therapeutic Devices, and Development Services. It earns the majority of revenue from the therapeutics segment, which consists of Assisi, PulseVet, and VETIGEL products.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 100 Phoenix Drive
  • Suite 190
  • Ann Arbor, MI 48108
  • United States
+1 (734)
Primary Industry
Other Healthcare Services
Other Industries
Diagnostic Equipment
Stock Exchange
OTCM
Vertical(s)
Corporate Office
  • 100 Phoenix Drive
  • Suite 190
  • Ann Arbor, MI 48108
  • United States
+1 (734)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Zomedica Pharmaceuticals Stock Performance

As of 20-Nov-2026, Zomedica Pharmaceuticals’s stock price is $0.08. Its current market cap is $78.5M with 980M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.08 $0.08 $0.07 - $0.16 $78.5M 980M 947K -$0.01

Zomedica Pharmaceuticals Financials Summary

As of 30-Sep-2026, Zomedica Pharmaceuticals has a trailing 12-month revenue of $38.7M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 36,093 48,939 42,796 91,731
Revenue 38,681 32,030 27,285 25,186
EBITDA (10,413) (76,620) (43,519) (34,845)
Net Income (15,995) (81,858) (46,982) (34,529)
Total Assets 115,026 127,039 207,360 253,197
Total Debt 1,648 2,184 1,814 2,730
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Zomedica Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Zomedica Pharmaceuticals‘s full profile, request access.

Request a free trial

Zomedica Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focu
Other Healthcare Services
Ann Arbor, MI
141 As of 2025

Emeryville, CA

Westbrook, ME
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Zomedica Pharmaceuticals Competitors (4)

One of Zomedica Pharmaceuticals’s 4 competitors is Grifols Diagnostic Solutions, a Corporate Backed or Acquired company based in Emeryville, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Grifols Diagnostic Solutions Corporate Backed or Acquired Emeryville, CA
Idexx Laboratories Formerly VC-backed Westbrook, ME
Ocugen Formerly VC-backed Malvern, PA
Antech Diagnostics Corporation Fountain Valley, CA
To view Zomedica Pharmaceuticals’s complete competitors history, request access »

Zomedica Pharmaceuticals Patents

Zomedica Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210024644-A1 N-cadherin binding molecules and uses thereof Inactive 25-Jul-2019
WO-2021016552-A1 N-cadherin binding molecules and uses thereof Inactive 25-Jul-2019
WO-2021007007-A1 Compositions and methods for diagnosing urinary tract infections Inactive 05-Jul-2019
US-20200172979-A1 Compositions and methods for identifying cancer Inactive 04-Dec-2018
WO-2020117809-A1 Compositions and methods for identifying cancer Inactive 04-Dec-2018 G16B20/10
To view Zomedica Pharmaceuticals’s complete patent history, request access »

Zomedica Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Zomedica Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Zomedica Pharmaceuticals‘s full profile, request access.

Request a free trial

Zomedica Pharmaceuticals Investments & Acquisitions (7)

Zomedica Pharmaceuticals’s most recent deal was a Merger/Acquisition with Qorvo Biotechnologies for . The deal was made on 05-Oct-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Qorvo Biotechnologies 05-Oct-2023 Merger/Acquisition Diagnostic Equipment
Structured Monitoring Products 05-Sep-2023 Merger/Acquisition Monitoring Equipment
Assisi Animal Health 15-Jul-2022 Merger/Acquisition Other Consumer Durables
Revo Squared 01-Jul-2022 Merger/Acquisition Business/Productivity Software
Structured Monitoring Products 19-May-2022 Secondary Transaction - Private Monitoring Equipment
You’re viewing 5 of 7 investments and acquisitions. Get the full list »

Zomedica Pharmaceuticals ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Healthcare

Industry

Rank

Percentile

Medical Devices

Subindustry

Rank

Percentile

To view Zomedica Pharmaceuticals’s complete esg history, request access »

Zomedica Pharmaceuticals Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Assisi Animal Health New Vernon, NJ 2010
PulseVet Technologies Roswell, GA 2009

Zomedica Pharmaceuticals FAQs

  • Where is Zomedica Pharmaceuticals headquartered?

    Zomedica Pharmaceuticals is headquartered in Ann Arbor, MI.

  • What is the size of Zomedica Pharmaceuticals?

    Zomedica Pharmaceuticals has 141 total employees.

  • What industry is Zomedica Pharmaceuticals in?

    Zomedica Pharmaceuticals’s primary industry is Other Healthcare Services.

  • Is Zomedica Pharmaceuticals a private or public company?

    Zomedica Pharmaceuticals is a Public company.

  • What is Zomedica Pharmaceuticals’s stock symbol?

    The ticker symbol for Zomedica Pharmaceuticals is ZOMDF.

  • What is the current stock price of Zomedica Pharmaceuticals?

    As of 20-Nov-2026 the stock price of Zomedica Pharmaceuticals is $0.08.

  • What is the current market cap of Zomedica Pharmaceuticals?

    The current market capitalization of Zomedica Pharmaceuticals is $78.5M.

  • What is Zomedica Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Zomedica Pharmaceuticals is $38.7M.

  • Who are Zomedica Pharmaceuticals’s competitors?

    Grifols Diagnostic Solutions, Idexx Laboratories, Ocugen, and Antech Diagnostics are competitors of Zomedica Pharmaceuticals.

  • What is Zomedica Pharmaceuticals’s annual earnings per share (EPS)?

    Zomedica Pharmaceuticals’s EPS for 12 months was -$0.01.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process